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Abstract
To elucidate the role of histamine in the pathogenesis of post-ischemic reperfusion injury of tissues, the effect of diamine
oxidase (DAO) was studied on the changes in renal functions induced by 30 min occlusion followed by reperfusion of the
renal vessels of unilaterally nephrectomized rats. Kinetic analysis using radiolabeled albumin revealed that vascular
permeability of the kidney increased markedly after reperfusion. Although the intensity of neutrophil-dependent
chemiluminescence of the blood remained unchanged during the occlusion, it increased significantly after reperfusion.
Histological examination revealed a marked degeneration of glomeruli and proximal tubules in the reperfused kidney.
Transtubular transport of phenolsulfophthalein (PSP) decreased markedly after reperfusion with concomitant increase in
plasma levels of creatinine. Intravenously administered DAO markedly inhibited the reperfusion-induced increase in vascular
permeability, preserved the structure of the kidney and normalized the rate of clearance of PSP and creatinine. Combined use
of diphenylhydramine and ranitidine also inhibited the reperfusion injury of the kidney. These results suggested that
histamine and its receptors might play critical roles in post-ischemic reperfusion injury of the kidney. ß 1998 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Warm ischemia of the kidney is often associat-
ed with an increase in plasma levels of creatinine
and focal destruction of tubular epithelial cells [1].
Normothermic ischemia and reperfusion of the kid-
ney of unilaterally nephrectomized rats resulted in
acute necrosis of renal tubules [2]. Despite extensive
studies on ischemia and reperfusion-induced
injury of the kidney, the mechanism and an e¡ec-
tive way to decrease renal injury remain to be
elucidated.
Pathogenic metabolites would be released into the
circulation during and/or after occlusion of the renal
vessels [3]. For example, histamine is released from
various types of cells, such as mast cells, basophilic
leukocytes and platelets, particularly under patho-
logic conditions [4]. When these cells are challenged
with various stimuli, they release histamine. Because
the small intestine is highly enriched with mast cells,
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short-term ischemia followed by reperfusion strongly
impairs their mucosal cells by a histamine-enhance-
able mechanism.
Diamine oxidase (DAO) is an enzyme which
degrades histamine. Intravenously injected DAO
circulates with a fairly long half-life (90 min)
and e¡ectively degrades histamine in plasma [5].
Hence, administration of DAO markedly decreased
post-ischemic reperfusion injury of the intestine
[6^8].
Although renal levels of histamine are relatively
low, its turnover in this tissue is fairly high [9,10].
Thus, histamine may also underlie the pathogenesis
of reperfusion injury of the kidney. The present work
demonstrates that intravenously administered DAO
markedly decreased post-ischemic reperfusion injury
of the kidney.
2. Materials and methods
2.1. Materials
Bovine serum albumin, histamine, luminol and zy-
mosan were purchased from Sigma Chemical Co. (St.
Louis, MO). Highly puri¢ed diamine oxidase (EC
1.4.3.6) from porcine kidney was obtained from
ICN Biochemicals (Cleveland, OH). 125I-Labeled
Bolton-Hunter reagent (2.2 Ci/mol) was obtained
from New England Nuclear (Boston, MA). Hista-
mine assay kit was obtained from Immunoteks
(France). PSP and heparin were purchased from
Daiichi Seiyaku Co. (Tokyo) and Nakarai Chemical
Co. (Kyoto), respectively. Diphenylhydramine (H1
antagonist) and ranitidine (H2 antagonist) were ob-
tained from Kowa Co. (Tokyo) and Sankyo Co. (To-
kyo), respectively. Other reagents used were of ana-
lytical grade. 125I-Labeled albumin was prepared as
described previously [11]. After dialysis against 0.15
M NaCl containing 5 mM sodium phosphate, pH
7.4, the radiolabeled albumin sample was used for
the experiments.
Long acting superoxide dismutase (SOD) deriva-
tive covalently linked with poly(styrene-co-maleic
acid butyl ester) was synthesized as described previ-
ously [12,13]. This SOD derivative circulates bound
to albumin with a half-life of 8 h.
2.2. Methods
Male Sprague-Dawley rats, 280^350 g, were used
after fasting for 16 h. Under light ether anesthesia,
the right kidney was nephrectomized 6 days before
experiments to increase the e¡ect of ischemia and
reperfusion of the left kidney. Rats were divided
into four groups. Numbers of animals used for
sham (laparotomized only), control (the left renal
artery and vein were occluded for 30 min), DAO-
treated (DAO-treated and occluded) and H1/H2-an-
tagonist-treated groups were 7, 8, 9 and 7, respec-
tively.
Under pentobarbital anesthesia (50 mg/kg body
weight), 2 ml of saline was intraperitoneally admin-
istered to the rat. Then, either DAO (0.5 U/kg body
weight) or saline (0.3 ml) was injected intravenously
as a bolus to the rat. In some experiments, 10 mg/kg
of either diphenylhydramine, ranitidine, or diphenyl-
hydramine plus ranitidine was administered intrave-
nously to the rat over a period of 10 s. After 15 min,
the left renal artery and vein were occluded for 30
min and reperfused thereafter. After 24 h of reperfu-
sion, renal functions of the animals were determined
under pentobarbital anesthesia. In some experiments,
blood pressure of the animals was monitored during
the experiments. Under the present experimental
conditions, a respirator was not required and blood
gases were not analyzed.
2.3. Renal accumulation of 125I-labeled albumin
Under pentobarbital anesthesia, heparin was in-
jected into the tail vein (500 U/kg body weight).
Then, the renal artery and vein were occluded for
30 min. Three min before reperfusion, 125I-labeled
albumin (1.5U105 cpm/kg body weight) was injected
intravenously (n = 7). After 30 min of reperfusion,
kidney and blood samples were obtained, and radio-
activity in the samples was determined in a scintilla-
tion counter (Aloka).
2.4. Renal function test
One day after reperfusion, renal functions were
determined by using PSP (n = 7^9). PSP was injected
into the left femoral vein (10 Wmol/kg body weight).
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At the indicated times after administration, 0.1 ml
blood samples were collected from the right femoral
vein. 100 Wl of saline was added to the samples and
they were centrifuged at 12 000Ug for 3 min. The
concentration of PSP in the supernatant fractions
was measured spectrophotometrically in 0.1 N
NaOH at 558 nm [14]. Plasma levels of creatinine
were also determined spectrophotometrically as de-
scribed previously [15].
2.5. Histological examination
The excised kidney was ¢xed with 10% formalin
and specimens were observed under light microscopy
after staining with hematoxylin and eosin (n = 7^9).
2.6. Analysis by luminol chemiluminescence
Before and during ischemia, and immediately after
reperfusion of the kidney, 0.1 ml blood samples were
obtained from the left renal vein. The samples were
quickly determined for luminol chemiluminescence
(n = 7) as described previously [16].
2.7. Determination of histamine in plasma
At the indicated times, 0.3 ml blood samples were
obtained from the left renal vein (n=7). Histamine
concentrations in plasma were determined by the
use of a histamine assay kit as described previously
[17,18].
2.8. Statistical analysis
Statistical analysis was performed using Student’s
t-test and variance. All results are expressed as the
mean þ S.E.M. derived from 7^9 animals.
3. Results
3.1. E¡ect of DAO on renal distribution of
125I-labeled albumin
Thirty minutes after reperfusion, the weight of the
kidney increased by about 18% (from 1.13 þ 0.12 to
1.38 þ 0.20 g, n = 8). Intravenous administration of
DAO completely inhibited the increase in the renal
weight (n = 9). Because the renal weight rapidly in-
creased in the reperfused group, vascular permeabil-
ity of the kidney might be increased during ischemia
and/or reperfusion. To test this possibility, 125I-la-
beled albumin was injected intravenously 3 min be-
fore reperfusion. Thirty minutes after reperfusion,
the kidney was perfused with 3 ml of ice-cold saline.
Then, the amounts of radioactivity in the kidney and
blood were determined. The ratio of radioactivity
found in the kidney to that in the blood increased
markedly in the reperfused group (Fig. 1). The in-
crease in the tissue/blood ratio was completely inhib-
ited by pretreating animals with DAO.
3.2. Histological examination
Because post-ischemic reperfusion markedly de-
creased the renal function, the structure of the kidney
might also be impaired in the reperfused group. To
test this possibility, histological examination of the
kidney was carried out 1 day after reperfusion. As
shown in Fig. 2, post-ischemic reperfusion caused a
marked injury of the kidney. Destruction of tubular
Fig. 1. E¡ect of DAO on renal distribution of 125I-labeled albu-
min. Under pentobarbital anesthesia, animals were intrave-
nously administered 0.3 ml of either saline or DAO (10 mg/kg)
just before occlusion of the renal artery and vein. After 27 min
of ischemia, radiolabeled albumin was injected intravenously
(150 000 cpm/kg body weight). Thirty minutes after reperfusion,
radioactivity in the kidney and blood (1 ml) was determined as
described in the text. Data show the mean þ S.E.M. derived
from 7 animals. *P6 0.01.
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basement membranes, vascular degeneration and ne-
crosis of tubular epithelial cells are apparent in the
reperfused group. Renal injury was more marked in
proximal tubules than in glomeruli. DAO markedly
suppressed the reperfusion injury.
3.3. Changes in plasma histamine levels
To determine the possible involvement of hista-
mine in the pathogenesis of renal injury, plasma lev-
els of histamine were measured with blood samples
collected from the left renal vein. Histamine levels in
plasma markedly increased during occlusion and re-
perfusion (Fig. 3). On the other hand, plasma hista-
mine levels were decreased markedly by treating ani-
mals with DAO.
3.4. E¡ect of histamine and DAO on reactive oxygen
generation by neutrophils in the blood
Neutrophil-dependent chemiluminescence intensity
was determined with normal blood samples in the
presence of varying concentrations of histamine. His-
tamine increased the chemiluminescence intensity of
the blood in a dose-dependent manner (Fig. 4). Final
concentrations of histamine used (1038-1036 M) were
similar to those found in plasma from the reperfused
group. To test the possible involvement of histamine
in the pathogenesis of renal injury, blood samples
were obtained from the left vein of the reperfused
group during the experiments. Chemiluminescence
intensity of blood samples increased after reperfusion
(Fig. 5). Administration of DAO slightly but signi¢-
cantly suppressed the chemiluminescence intensity
particularly at 40 min after reperfusion.
Fig. 2. E¡ect of DAO on the reperfused kidney. Twenty-four
hours after reperfusion, the kidney specimens were subjected to
histological analysis by staining with hematoxylin and eosin.
Data show one typical experiments of 7^9 animals. (a) Sham-
operated group; (b) reperfused control group; (c) DAO-treated
group. (U40.)
Fig. 3. E¡ect of ischemia and reperfusion on plasma histamine
levels. At the indicated times, 0.3 ml blood samples were col-
lected from the left renal vein and determined for plasma levels
of histamine as described in the text. Data show the mean þ
S.E.M. derived from 7 animals. Triangles, sham-operated
group;, closed circles, reperfused group; open circles, DAO-
treated groups. *P6 0.01.
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3.5. E¡ect of DAO and related compounds on renal
functions
Intravenously injected PSP rapidly disappeared
from the circulation of normal rats (Table 1). The
rate of PSP disappearance decreased signi¢cantly in
the reperfused group. The decrease in the rate of PSP
disappearance was markedly inhibited by administra-
tion of DAO.
To elucidate the e¡ect of post-ischemic reperfusion
on renal glomerular functions, plasma levels of crea-
tinine were measured 24 h after reperfusion. Creati-
nine levels in the reperfused group (6.3 mg/dl) were
signi¢cantly higher than in the sham-operated group.
Administration of DAO completely inhibited the in-
crease in plasma creatinine levels.
To test the possible involvement of histamine in
the mechanism of reperfusion injury of the kidney,
e¡ects of H1 and H2 antagonists were examined on
the changes in renal functions induced by reperfu-
sion. Administration of either diphenylhydramine
or ranitidine slightly inhibited the reperfusion-in-
duced decrease in PSP clearance and the increase in
plasma creatinine levels. However, combined use of
the two antagonists markedly increased the rate of
PSP disappearance and decreased plasma creatinine
levels.
4. Discussion
The present work demonstrates that DAO e¡ec-
tively inhibited the post-ischemic reperfusion injury
of the kidney. Although morphological changes in
the kidney were not apparent during ischemia,
pathologic metabolism leading to reperfusion-in-
duced injury would have been triggered during the
occlusion of renal vessels. Among various metabo-
lites, histamine has been known to increase vascular
permeability and induce tissue injury [19,20]. This is
consistent with the prevent ¢ndings that DAO inhib-
ited the increase in vascular permeability and de-
crease in renal functions. These observations suggest
that injury of renal vascular endothelial cells may
underlie the pathogenesis of reperfusion injury.
Because the blood samples for histamine analysis
were obtained from the renal vein, the elevated his-
tamine might derive from the reperfused kidney. In
fact, although the number of mast cells and levels of
histamine in the kidney are relatively low, the turn-
Fig. 4. E¡ect of histamine on neutrophil-dependent chemilumi-
nescence. Blood samples (0.1 ml) were collected from the left
renal vein into tubes containing 400 ml of MEM and 0.1 mM
luminol. In the presence of varying concentrations of histamine,
chemiluminescence intensity was determined at 25‡C at 1
(circles) and 10 min (triangles) after adding 50 Wl of opsonized
zymosan (12.5 mg/ml). Data show the mean þ S.E.M. derived
from 7 animals.
Fig. 5. E¡ect of ischemia and reperfusion on neutrophil-depend-
ent chemiluminescence. At the indicated times, 0.1 ml blood
samples were obtained from the left renal vein and chemilumi-
nescence intensity determined as described in Fig. 4. Data show
the mean þ S.E.M. derived from 7 animals. Triangles, sham-op-
erated group; closed circles, reperfused group; open circles,
DAO-treated group. *P6 0.01.
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over of histamine is fairly high in this tissue [9,10].
Furthermore, the kidney has considerable activity of
histidine decarboxylase [21]. Thus, histamine would
be generated and/or metabolized in the kidney par-
ticularly when renal circulatory status was perturbed.
Consistent with this notion is the report that gener-
ation of histamine in renal cortex increased propor-
tionally to that in glomeruli [22]. Furthermore, ad-
ministration of histidine markedly increased the
urinary excretion of histamine. Thus, the kidney
might be the major source of the elevated histamine
in the blood obtained from the renal vein. Because
the hemodynamics changed markedly after occlusion
and reperfusion of the renal vessels, the circulating
leukocytes and platelets might be activated under the
present experimental conditions. Therefore, hista-
mine derived from these blood cells and other tissues
may also participate in enhancing the reperfusion
injury of the kidney. The cellular source of histamine
responsible for reperfusion injury of the kidney
should be studied further.
Ichikawa et al. [23] suggested that histamine
bound to H1 receptors on renal glomeruli of Munich
Wistar rats. Although the presence of H2 receptors in
rat kidney is uncertain, both H1 and H2 receptors are
localized in the kidney of mongrel dogs [24].
Although the single use of diphenylhydramine or ra-
nitidine inhibited the reperfusion injury only slightly,
the combined use of the two antagonists markedly
inhibited the injury. This observation suggests that
both H1 and H2 receptors might also be localized
in rat kidney and play critical roles in the pathogen-
esis of reperfusion injury. However, the possible in-
volvement of metabolites other than histamine in the
pathogenesis of reperfusion injury should be studied
further.
It should be noted that pathologic metabolisms,
such as conversion of xanthine dehydrogenase to
xanthine oxidase and ATP to xanthine and hypoxan-
thine, are enhanced by long-term ischemia [25]. Thus,
factors other than histamine, such as reactive oxygen
species, might also play a role in the pathogenesis of
reperfusion injury. In this context, histamine in-
creased the chemiluminescence intensity of the blood
in a dose-dependent manner. Because chemilumines-
cence intensity of the blood obtained from the renal
vein increased markedly after reperfusion, the re-
leased histamine might increase oxidative stress by
stimulating circulating leukocytes. Consistent with
this notion is the ¢nding that a long acting SOD
which circulates with a half-life of 6 h [9] also inhib-
ited the re£ow-induced injury of the brain [26], heart
[27], liver [28] and stomach [29].
Because post-ischemic reperfusion is known to de-
crease systemic blood pressure [30], such a change in
the circulation status may also underlie the patho-
genesis of reperfusion injury of the kidney. To test
this possibility, the e¡ect of DAO on blood pressure
was observed during ischemia and reperfusion. Intra-
venous administration of DAO (0.5 U/kg) rapidly
but transiently increased the blood pressure of nor-
mal rats from 120 to 180 mm Hg, returning to con-
trol levels within 100 min. These observations suggest
that histamine might decrease the blood pressure
thereby a¡ecting the circulatory status of animals
during ischemia and/or reperfusion.
Because transient occlusion of renal vessels is
sometimes required for the operation of aneurysms
Table 1
E¡ect of DAO on PSP clearance and plasma creatinine
Experimental group PSP (WM) Creatinine (mg/dl)
1 min 6 min 10 min
Sham 75 þ 12 38 þ 5 29 þ 8 2.2 þ 0.3
Control 90 þ 22 52 þ 17 43 þ 13 6.3 þ 2.5
+DAO 72 þ 15* 40 þ 6* 31 þ 3 2.0 þ 0.5**
+Diphenylhydramine 87 þ 30 42 þ 19 31 þ 15 4.5 þ 2.5
+Ranitidine 81 þ 28 45 þ 24 36 þ 17 4.6 þ 2.7
+Diphenylhydramine and ranitidine 47 þ 11* 28 þ 6** 24 þ 6** 3.9 þ 2.3*
Changes in plasma levels of PSP and creatinine were determined as described in the text. Data show the mean þ S.E.M. derived from
7^9 animals. Detailed conditions are described in the text. *P6 0.05, **P6 0.01
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in the abdominal aorta and for renal transplantation,
similar changes in the metabolism of histamine and
related compounds may also occur in such patients.
Thus, the pathologic signi¢cance of histamine should
also be studied in patients who receive surgery in-
volving transient occlusion of renal blood vessels.
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